A Phase 2 interventional study of Spironolactone and Placebo in Arrhythmogenic Right Ventricular Dysplasia, sponsored by Hospices Civils de Lyon. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Hospices Civils de Lyon · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia.
Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of the RV function in patients with ARVD.
The investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at least reduce the deterioration of the RV function. The aim of this project is to evaluate the effect of spironolactone, a Potassium-sparing diuretic on ventricular myocardial remodeling and on arrhythmia burden in patients with ARVD.
The trial is a double-blind parallel multicenter prospective randomized phase II drug study. Patients will be randomized in the two groups: spironolactone or placebo. 13 centers in France will enroll the 120 patients (60 per group). Patients will be followed for 3 years (6 months, 1 year and 3 years) with all examinations (ECG, HA ECG, 24-hour Holter, trans-thoraciqc echocardiography (TTE), biological analyses) according to standard of care. A decrease in right and/or left ventricular deterioration and in arrhythmia burden are expected in ARVD patients treated with spironolactone. This reduction will improve the quality of life of patients and will reduce the number of hospitalizations and the risk of terminal heart failure.
49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.
This study's planned enrollment of 120 is above the median of 22 across 15 interventional studies indexed under Arrhythmogenic Right Ventricular Dysplasia.
Browse Arrhythmogenic Right Ventricular Dysplasia studies →Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Spironolactone
Drug: Placebo
The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
Right ventricle longitudinal strain measured by echocardiography
Time frame: at year 1
Right ventricle infundibulum diameter measured by echocardiography
Time frame: at year 1
number of ventricular extrasystoles > 500 on 24h-Holter ECG
Time frame: at year 1
number of ventricular extrasystoles on 24h-Holter ECG
Time frame: at year 1
number of palpitations
Time frame: at year 1
number of palpitations
Time frame: at year 3
number of ventricular tachycardia
Time frame: at year 1
number of ventricular tachycardia
Time frame: at year 3
number of dyspnea
Time frame: at year 1
number of dyspnea
Time frame: at year 3
number of syncope
Time frame: at year 1
number of syncope
Time frame: at year 3
number of sudden death
Time frame: at year 1
number of sudden death
Time frame: at year 3
number of thoracic pain
Time frame: at year 1
number of thoracic pain
Time frame: at year 3
number of MACE (Major adverse cardiac events)
Time frame: at year 1
number of MACE (Major adverse cardiac events)
Time frame: at year 3
number of hospital admissions
Time frame: at year 1
number of hospital admissions
Time frame: at year 3
left ventricle diameters measured by echocardiography
Morphologic criterion
Time frame: at year 1
left ventricle diameters measured by echocardiography
Morphologic criterion
Time frame: at year 3
left ventricle volumes measured by echocardiography
Morphologic criterion
Time frame: at year 1
left ventricle volumes measured by echocardiography
Morphologic criterion
Time frame: at year 3
left ventricle ejection fraction measured by echocardiography
Morphologic criterion
Time frame: at year 1
left ventricle ejection fraction measured by echocardiography
Morphologic criterion
Time frame: at year 3
Left ventricular global longitudinal strain measured by echocardiography
Morphologic criterion
Time frame: at year 1
aneurism measured by echocardiography
Morphologic criterion
Time frame: at year 1
aneurism measured by echocardiography
Morphologic criterion
Time frame: at year 3
dyskinesia measured by echocardiography
Morphologic criterion
Time frame: at year 1
dyskinesia measured by echocardiography
Morphologic criterion
Time frame: at year 3
evolution of QRS width (50mm/s) on ECG
Morphologic criterion
Time frame: at year 1
number of ventricular extrasystoles on 24h Holter ECG
Rhythmic criterion
Time frame: at year 1
sustained ventricular tachycardia on 24h Holter ECG
Rhythmic criterion
Time frame: at year 1
evolution of PR interval duration on ECG
Rhythmic criterion
Time frame: at year 1
late potentials measured with high amplification ECG
Rhythmic criterion
Time frame: at year 3
number of ventricular extrasystoles by stress test
Rhythmic criterion
Time frame: at year 3
Evolution of functional symptoms by recording adverse events
Functional criteria
Time frame: at year 3
Number of hospital admissions owing to clinical deterioration
Time frame: at year 3
Evolution of telediastolic right ventricle volume measured by echocardiography
according to the genotype of desmosome genes
Time frame: at year 3
arrhythmia burden measured by 24h Holter ECG
according to the genotype of desmosome genes
Time frame: at year 3
Dosage of MMP9 (Matrix metallopeptidase 9)
Quantification of fibrosis
Time frame: at year 1
Dosage of MMP9 (Matrix metallopeptidase 9)
Quantification of fibrosis
Time frame: at year 3
Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)
Quantification of fibrosis
Time frame: at year 1
Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)
Quantification of fibrosis
Time frame: at year 3
Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)
Quantification of fibrosis
Time frame: at year 1
Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)
Quantification of fibrosis
Time frame: at year 3
Dosage of IL6 (Interleukin 6)
Quantification of inflammation
Time frame: at year 1
Dosage of IL6 (Interleukin 6)
Quantification of inflammation
Time frame: at year 3
Dosage of IL8 (Interleukin 8)
Quantification of inflammation
Time frame: at year 1
Dosage of IL8 (Interleukin 8)
Quantification of inflammation
Time frame: at year 3
Plan to share: Undecided
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spironolactone
Arrhythmogenic Right Ventricular Dysplasia →